Genmab’s CLL drug gets negative opinion from EMA committee
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer
Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Sanofi to add future payments onto Medivation offer, according to reports
June 23, 2016Research and Development, Sales and Marketing Medivation, Sanofi
Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData
June 23, 2016Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum
The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …
Biogen promotes Paul McKenzie to executive vice president
June 23, 2016Biogen (Nasdaq: BIIB) has promoted Paul McKenzie to the role of executive vice president for pharmaceutical operations & technology, effective July …
AstraZeneca set to lose out on $80 million after US turns down flu vaccine
June 23, 2016Sales and Marketing AstraZeneca, CDC, flu, flu vaccine
AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …
Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study
June 23, 2016Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
New Humira data shows improved quality of life in ulcerative colitis patients
June 23, 2016Research and Development AbbVie, Humira, data, ulcerative colitis
New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …
Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits
June 22, 2016Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial
UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …
Wave Life Sciences granted FDA orphan drug designation for Huntington’s disease drug
June 22, 2016Research and Development FDA, drug, huntington's disease, wave life sciences
Wave Life Sciences (NASDAQ: WVE) has announced that it has received orphan drug designation for the US Food and Drug …
Takeda begins world’s first norovirus vaccine field trial
June 22, 2016Research and Development Takeda, Vaccine, norovirus
Takeda Pharmaceuticals (TSE: 4502) has announced that the first patient has received a dosage of their norovirus vaccine candidate, TAK-214, …
Immunomedics’ chief financial officer resigns, shares fall
June 22, 2016Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market
Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
Nice backs two cancer drugs from Novartis
June 22, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
Impax to acquire Teva, Allergan generic drugs for $586 million
June 22, 2016Research and Development, Sales and Marketing Allergan, Impax, Teva, generics
Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …
Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb
June 21, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer
Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …
Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study
June 21, 2016Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics
US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …
Auris Medical initiates Phase III trial for sudden deafness treatment
June 21, 2016Manufacturing and Production, Research and Development auris medical, sudden deafness
Auris Medical (NASDAQ: EARS) has announced that it has initiated enrolment for a new Phase III trial that will evaluate …
Novartis aims to launch five major global biosimilars by 2020
June 21, 2016Manufacturing and Production, Research and Development 2020, Novartis, Sandoz, biosimilars
Novartis (VTX: NOVN) has announced plans to triple its biosimilar portfolio by 2020, with the launch of five major biosimilar …
Doctors prescribe more brand drugs for free meals from pharma industry – Study
June 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing JAMA, regulation, research
Doctors who received free meals from the pharmaceutical representatives were more likely to prescribe the brand-name medication that was being …
First-in-man Zika vaccine trials get green light
June 21, 2016Manufacturing and Production, Research and Development trials, zika vaccine
Inovio Pharmaceuticals (NASDAQ: INO) and GeneOne Life Science (KSE: 011000) have announced that approval has been granted for the commencement …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
